Chemical Structure (Camptosar 01)
Camptosar Injection, Solution
Product Images NDC 0009-7529
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Camptosar (NDC 0009-7529). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Camptosar 02)
Figure 2 (Camptosar 03)
This appears to be a chart or graph depicting survival rates over time for a study involving Irinotecan and 5-FU/LV. The x-axis shows months and the y-axis represents survival probability. However, without more context or information it is difficult to interpret the chart accurately.*
Figure 3 (Camptosar 04)
Figure 4 (Camptosar 05)
This is a comparison study of Irinotecan and 5-FU in 127 and 129 individuals respectively. The median follow-up period was 15 months. However, due to the limited text, it is not clear what the numbers under "Median (mo)" represent. There is mention of a log-rank test and months, but no details are provided about what this means.*
Logo (Camptosar 06)
This is a description of a product called "Injectables". The product is distributed by a company named "Pharmacia & Upjohn Co", which is a division of "Pfizer Inc" located in NY, NY 10017.*
Principal Display Panel (100 mg/5 mL Vial Label)
This is a description of a medication called Camptosar® (irinotecan HCI injection) used for intravenous use only. It comes in a Cytosafe® vial, contains 100mg/5mL (20mg/mL) of a sterile, aqueous solution and should be stored at room temperature between 15°C to 30°C (59° to 86°F) while being protected from light and freezing. The packaging warns that it is a cytotoxic agent and advises to discard any unused portion. The dosage and use instructions can be found in the accompanying prescribing information. It is distributed by Pharmacia & Upjohn Co division of Pfizer Inc in New York, NY and was made in Australia. There is a lot and expiration date on the packaging as well.*
Principal Display Panel (100 mg/5 mL Vial Carton)
Camptosar® is an injectable medication for intravenous use only, containing irinotecan hydrochloride. It is a cytotoxic agent, used for cancer treatment, specifically, metastatic colorectal cancer. The dosage and use of Camptosar® must be determined according to the prescribing information. The medication should be stored at a controlled room temperature between 16°C to 30°C and protected from light, freezing, and damage or leakage in transit. The package is for a single-dose only and unused portions must be discarded, as per instructions.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
